New surfactant for preterm babies with respiratory distress syndrome: a first-in-human study
Apr 06, 2018•10 min•Ep. 163
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
What’s the safety and tolerability of the new enriched synthetic surfactant CHF5633?
Associate Editor of ADC FN Jonathan Davis is joined by David Sweet (Royal Maternity Hospital, Belfast) to discuss a first-in-human clinical study of two human surfactant proteins in preterm babies with respiratory distress syndrome.
Read the Archives of Disease in Childhood: Fetal & Neonatal's open access paper "A first-in-human clinical study of a new SP-B and SP-C enriched synthetic surfactant (CHF5633) in preterm babies with respiratory distress syndrome": http://fn.bmj.com/content/102/6/F497.
For the best experience, listen in Metacast app for iOS or Android